Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma

Cancer Gene Therapy

Volumn 13, Issue 3, 2006, Pages 306-317

  Kamstock, D ^a   Guth, A ^a   Elmslie, R ^b   Kurzman, I ^c   Liggitt, D ^d   Coro, L ^a   Fairman, J ^e   Dow, S ^a,f  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Veterinary Referral Center of Colorado   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Urigen Pharmaceuticals Inc   (United States)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Canine; Endostatin; Endothelial; Gene; Immune; Tumor

Indexed keywords

DNA; ENDOSTATIN; LIPOSOME; PLASMID DNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; GENE EXPRESSION; GENE TARGETING; NONHUMAN; PRIORITY JOURNAL; SOFT TISSUE CANCER; TUMOR BIOPSY; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; DNA; DOG DISEASES; DOGS; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FIBROSARCOMA; GENETIC VECTORS; INFUSIONS, INTRAVENOUS; LIPOSOMES; LUCIFERASES; MICE; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA; SKIN NEOPLASMS; SPLEEN; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; CANIS FAMILIARIS; RODENTIA;

EID: 32844473094     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700895     Document Type: Article

References (54)

1. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
2. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003; 2: S127-S133.
3. Folkman J. Endogenous angiogenesis inhibitors. Apmis 2004; 112: 496-507.
4. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-515.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.
6. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
7. Ziche M, Donnini S, Morbidelli L. Development of new drugs in angiogenesis. Curr Drug Targets 2004; 5: 485-493.
8. Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3: 263-276.
9. Heymach JV, Desai J, Manola J, Davis D, McConkey J, Harmon D et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10: 5732-5740.
10. Iqbal S, Lenz HJ. Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol 2004; 31: 10-16.
11. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J et al. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 2004; 10: 88-95.
12. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-1264.
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
14. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
15. Eder Jr JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20: 3772-3784.
16. Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A et al. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 2001; 51: 11-18.
17. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998; 95: 9064-9066.
18. Jin X, Bookstein R, Wills K, Avanzini J, Tsai V, LaFace D et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther 2001; 8: 982-989.
19. Li PY, Lin JS, Feng ZH, He YF, Zhou HJ, Ma X et al. Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent antitumor effect on hepatoma. World J Gastroenterol 2004; 10: 2195-2200.
20. Nakashima Y, Yano M, Kobayashi Y, Moriyama S, Sasaki H, Toyama T et al. Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Therapy 2003; 10: 123-130.
21. Blezinger P, Yin G, Xie L, Wang J, Matar M, Bishop JS et al. Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models. Angiogenesis 1999; 3: 205-210.
22. Chen QR, Kumar D, Stass SA, Mixson AJ. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 1999; 59: 3308-3312.
23. Davidoff AM, Nathwani AC. Antiangiogenic gene therapy for cancer treatment. Curr Hematol Rep 2004; 3: 267-273.
24. Dutour A, Monteil J, Paraf F, Charissoux JL, Kaletta C, Sauer B et al. Endostatin cDNA/Cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther 2005; 11: 311-319.
25. Hong SY, Lee MH, Kim KS, Jung HC, Roh JK, Hyung WJ et al. Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World J Gastroenterol 2004; 10: 1191-1197.
26. Indraccolo S. Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther 2004; 4: 297-308.
27. Regulier E, Paul S, Marigliano M, Kintz J, Poitevin Y, Ledoux C et al. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther 2001; 8: 45-54.
28. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003; 66: 1-9.
29. Subramanian IV, Ghebre R, Ramakrishnan S. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Therpy 2005; 12: 30-38.
30. Sun X, Qiao H, Jiang H, Zhi X, Liu F, Wang J et al. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005; 12: 35-45.
31. Szala S, Szary J, Cichon T, Sochanik A. Antiangiogenic gene therapy in inhibition of metastasis. Acta Biochim Pol 2002; 49: 313-321.
32. Wang L, Schmitz V, Perez-Mediavilla A, Izal I, Prieto J, Qian C. Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther 2003; 8: 72-79.
33. Yano M, Nakashima Y, Kobayashi Y, Mizuno K, Konishi A, Sasaki H et al. Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection. Cancer Gene Ther 2004; 11: 354-362.
34. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401-1413.
35. Eichhorn ME, Strieth S, Krasnici S, Sauer B, Teifel M, Michaelis U et al. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 2004; 7: 133-141.
36. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163: 1552-1561.
37. Whitmore MM, Li S, Falo Jr L, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 2001; 50: 503-514.
38. Siders WM, Vergillis K, Johnson C, Scheule RK, Kaplan JM. Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination. Mol Ther 2002; 6: 519-527.
39. Withrow SJ. Soft tissue sarcomas. Vet Q 1998; 20(Suppl 1): S16-S17.
40. Rassnick KM. Medical management of soft tissue sarcomas. Vet Clin N Am Small Anim Pract 2003; 33: 517-531.
41. Ettinger SN. Principles of treatment for soft-tissue sarcomas in the dog. Clin Tech Small Anim Pract 2003; 18: 118-122.
42. Dow S, Elmslie R, Kurzman I, Macewen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005; 16(8): 937-946.
43. Fairman J, Roche L, Pieslak I, Lay M, Corson S, Fox E et al. Quantitative RT-PCR to evaluate in vivo expression of multiple transgenes using a common intron. Biotechniques 1999; 27: 566-570, 572-564.
44. Liu Y, Mounkes LC, Liggitt HD, Brown CS, Solodin I, Heath TD et al. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat Biotechnol 1997; 15: 167-173.
45. Dow SW, Elmslie RE, Fradkin LG, Liggitt DH, Heath TD, Willson AP et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther 1999; 10: 2961-2972.
46. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
47. Scheidegger P, Weiglhofer W, Suarez S, Kaser-Hotz B, Steiner R, Ballmer-Hofer K et al. Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs. Biol Chem 1999; 380: 1449-1454.
48. Clifford CA, Hughes D, Beal MW, Henry CJ, Drobatz KJ, Sorenmo KU. Vascular endothelial growth factor concentrations in body cavity effusions in dogs. J Vet Intern Med 2002; 16: 164-168.
49. Allen DK, Waters DJ, Knapp DW, Kuczek T. High urine concentrations of basic fibroblast growth factor in dogs with bladder cancer. J Vet Intern Med 1996; 10: 231-234.
50. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Therapy 1999; 6: 1867-1875.
51. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
52. Koski GK, Czerniecki BJ. Combining innate immunity with radiation therapy for cancer treatment. Clin Cancer Res 2005; 11: 7-11.
53. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11: 361-369.
54. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 2004; 64: 5074-5077.